• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    1/24/23 5:04:22 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    SC 13G/A 1 ea172143-13ga2alpha_icecure.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 2)

     

    ICECURE MEDICAL LTD.

     

    (Name of Issuer)

     

    ORDINARY SHARES, NO PAR VALUE

     

    (Title of Class of Securities)

     

    M53071136

     

    (CUSIP Number)

     

    December 31, 2022

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

     

     

    Page 1 of 5 Pages

     

     

     

     

    CUSIP No. M53071136   13G/A   Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON
       
        S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
         
        Alpha Capital Anstalt
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
       
        (a) ☐
        (b) ☐
    3. SEC USE ONLY
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION - Liechtenstein
       
    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 290,378 Ordinary Shares (1)

       
    6.   SHARED VOTING POWER - None
       
    7.   SOLE DISPOSITIVE POWER – 290,378 Ordinary Shares (1)
       
    8.   SHARED DISPOSITIVE POWER – None
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
           
        290,378 Shares of Common Stock (1)  
    10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☒
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
       

    0.789% (1)

    12. TYPE OF REPORTING PERSON
           
        CO

     

    (1)

    Based on 36,835,554 shares outstanding as of December 20, 2022 as reported in the Form 424B5 filed with the Securities and Exchange Commission on December 22, 2022.

     

     

     

     

    CUSIP No. M53071136   13G/A   Page 3 of 5 Pages

     

    ITEM 1 (a) NAME OF ISSUER: IceCure Medical Ltd., an Israeli corporation

     

    ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    7 Ha’Eshel Street, P.O. Box 3163, Caesarea, Israel 3079504

     

    ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    Altenbach 8, FL-9490 Vaduz, Liechtenstein

     

    ITEM 2 (c) CITIZENSHIP: Liechtenstein

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Ordinary Shares, no par value

     

    ITEM 2 (e) CUSIP NUMBER: M53071136

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4 OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 290,378 Ordinary Shares (1)

     

    (b) PERCENT OF CLASS: 0.789% (1)

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    290,378 Ordinary Shares (1)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    290,378 Ordinary Shares (1)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

     

    CUSIP No. M53071136   13G/A   Page 4 of 5 Pages

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Alpha Capital Anstalt’s ownership is now below 5%.

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    CUSIP No. M53071136   13G/A   Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      January 24, 2023
      (Date)
       
      /s/ Konrad Ackermann
      (Signature)
       
      Konrad Ackermann, Director
      (Name/Title)

     

     

     

    Get the next $ICCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

      CAESAREA, Israel, July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the subscription period of its previously announced rights offering (the "Rights Offering") expired at 5:00 p.m., Eastern Time, on July 28, 2025. As previously disclosed, the Company distributed to all holders of record of the Company's ordinary shares, no par value per share ("Ordinary Shares") as of 5:00 p.m., Eastern Time, on July 9, 2025 (the "Record Date"), at no charge, non-transferable subscription righ

      7/29/25 9:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

      Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoabla

      7/25/25 9:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

      CAESAREA, Israel, July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, reminds rights holders that the subscription period for its previously announced rights offering (the "Rights Offering") expires at 5:00 PM Eastern Time on Monday, July 28, 2025.   Pursuant to the Rights Offering, the Company distributed to all holders of record of the Company's ordinary shares, no par value per share ("Ordinary Shares") as of 5:00 p.m., Eastern Time, on July 9, 2025 (the "Record Date"), at no charge, non-transfe

      7/24/25 9:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    SEC Filings

    See more
    • SEC Form 424B3 filed by IceCure Medical Ltd.

      424B3 - IceCure Medical Ltd. (0001584371) (Filer)

      7/28/25 7:48:24 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by IceCure Medical Ltd.

      6-K - IceCure Medical Ltd. (0001584371) (Filer)

      7/28/25 7:26:35 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by IceCure Medical Ltd.

      6-K - IceCure Medical Ltd. (0001584371) (Filer)

      7/25/25 9:05:02 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital initiated coverage on Icecure Medical with a new price target

      Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

      2/2/22 11:13:08 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners initiated coverage on Icecure Medical with a new price target

      Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

      9/22/21 8:10:09 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Financials

    Live finance-specific insights

    See more
    • IceCure Medical Reports First Quarter 2025 Financial Results

      Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, May 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2025. IceCure delivered its proposed post

      5/28/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

      CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is

      5/21/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

      Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin

      3/27/25 8:30:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    See more
    • IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

      Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

      8/28/23 8:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

      Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin

      12/6/22 8:00:00 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

      CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie

      11/29/21 1:07:00 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      11/14/24 9:38:43 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      2/14/23 8:46:31 AM ET
      $ICCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

      SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

      1/24/23 5:04:22 PM ET
      $ICCM
      Medical/Dental Instruments
      Health Care